The FDA has approved J&J's (JNJ) Invokana drug for treating type 2 diabetes in a new way by causing the body to excrete blood sugar via the urine rather than affecting the supply or use of insulin. The agency said J&J must carry out five post-marketing studies to determine whether the drug increases the risks of strokes, heart attacks and other side effects. Invokana is forecast to generate sales of $667M by 2016.
The FDA has approved J&J's (JNJ) Invokana drug for treating type 2 diabetes in a new way by...
From other sites
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs